Diabetes Connections | Type 1 Diabetes

Doug Scalia has completed 25 marathons in 15 states. He's about to add three more to his list, including the New York City Marathon as part of a team of people with type 1. He knows it sounds like an impossible feat for many, but he says anyone can do it! Doug was diagnosed as a young adult and he's also played in the World Series of Poker so we have a lot to talk about. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Beyond Type Run and Doug's team Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant. This was in rats.. but they achieved glycemic control without insulin injections and without immunosuppressive drugs for four months. AdoShell Islets is an immuno-protective synthetic biomaterial that secrets insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host's immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets. These researchers are optimistic that their unique approach can be translated from one species to another. https://www.labiotech.eu/trends-news/adocia-implants-diabetes/ XX Can starting a closed loop system right away help keep kids with type 1 in the honeymoon stage longer? New study says.. probably not. The latest findings are from the Closed Loop From Onset in Type 1 Diabetes (CLOuD) trial, a multicenter, open-label, parallel-group, randomized study, published online September 7 in the New England Journal of Medicine by Charlotte K. Boughton, PhD, and colleagues. In CLOuD, 97 youths aged 10-17 years were randomized to hybrid closed-loop therapy or standard insulin therapy (control) within 21 days of type 1 diabetes diagnosis. I found this a bit confusing, in the standard insulin therapy groups, participants could switch to insulin pump therapy or use flash or continuous glucose monitoring (CGM) or approved closed-loop systems if clinically indicated. So this isn't comparing an AID system to MDI. At 12 months, there were no differences after a mixed-meal tolerance test, with levels declining in both groups and dropping further by 24 months. Interestingly, they said glycemic control didn't differ significantly between the two groups. https://www.medscape.com/viewarticle/980356 XX Moving closer to a non-invasive way to measure blood glucose. The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute. This looks to be about the size of a Libre 3 or Dexcom G7.. It's said to have smart alarms and remote monitoring capability and just sticks on the skin. The MARD is 10 point 4, which is less accurate than CGMs on the market now, but much better than any other noninvasive device to make it this far. In addition to measuring blood glucose the makers say it can measure oxygen levels, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. Pivotal clinical study later this year and then the say they'll submit for European approval. https://www.med-technews.com/news/latest-medtech-news/glucorx-and-cardiff-university-to-bring-out-non-invasive-con/ XX RESEARCHERS in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes, before children develop symptoms or need insulin. They're offering a finger stick test when children have their pre-school vaccination. Very small start, only 60 kids, but these researchers say with a recent, more accurate test to check for markers early on, they hope to find more children before DKA sets in. https://www.oxfordmail.co.uk/news/20977659.oxford-scientists-launch-study-early-markers-type-1-diabetes-children/ XX The first Randomized Controlled Trial on open source automated insulin delivery (AID) is now published in a peer-reviewed medical journal. Big news for and from the we are not waiting crowd. The CREATE Trial evaluated the efficacy and safety of an open-source system using the OpenAPS algorithm in a modified version of AndroidAPS. This study included children and adults and found that across all ages, time in range was 14 percent higher than those who used commercial hybrid closed loop systems. There's more to it, and I"ll link it up, but this s

Omnipod 5 was approved earlier this year and just rolled out to a wider release. So how is the first tubeless automated insulin delivery system doing in the real world? We put together a panel of early adopters and got their feedback. That was great, but it brought up quite a few questions, so we reached out to Omnipod for clarification and follow up. The result is a super-sized episode full of info! Our panel: Liat Kochavi, mother an almost-8-year-old with T1D, Stephanie Williams, mother of a teen with type 1, and Sam Durante who was diagnosed with type 1 just before she turned 16. You'll also here from Insulet's Director of Medical Affairs Alex Nyugen, RD, CDCES. FYI, we were fortunate to speak with Insulet earlier this year, just after the FDA approval, and really went point by point through Omnipod 5. So we're not rehashing everything here. If you missed that episode, here's the link: Omnipod 5 interview from Feb 2022 Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more! Learn about the T1d Exchange: www.t1dexchange.org/stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story.. very early on here, but some progress in oral insulin for type 1. A team at University of British Columbia has developed a different kind of tablet that isn't made for swallowing, but instead dissolves when placed between the gum and cheek. This method delivered all the insulin to the liver without wasting or decomposing any insulin along the way. That's a big change from earlier studies and methods. The oral tablets absorb after about half an hour and last for up to four hours.. long way to go, no human trials yet. The the lead researcher on this project has a father with type 1 . https://www.sciencedaily.com/releases/2022/08/220830093215.htm?fbclid=IwAR1AzjI5UJma9I6g4hST044FS0MbJnUA0EXCmKXyhcOiOKL-ckIQTO4h8dY XX The type 2 diabetes drug dapagliflozin might also be used to help people with heart failure. A new study at Brigham and Women's Hospital showed that dapagliflozin – sold under the brand name Farxiga - reduced the risk of a cardiovascular death, or worsening heart failure, regardless of ejection fraction. Ejection fraction is a term that basically refers to how much blood is pumped out by the left ventricle of the heart each time it contracts. That's important because this drug has already been shown to help people who have the reduced pumping. And that's a lot more people. Big study here, more than 12-thousand people with lots of ages and races, benefits consistent throughout. https://www.bostonglobe.com/2022/08/29/business/brigham-womens-researchers-say-diabetes-drug-helps-reduce-heart-failure/ XX I hesitate to bring this study up, but it's gotten a lot of attention this week. It shows tight control of blood sugar in teens with Type 1 diabetes may help reduce the disease's damaging effects on the brain. But this small study from Nemours Children's Health, Jacksonville and Stanford University School of Medicine didn't release any numbers, n other words, it's not clear what they mean by tight control or at what level they're referring to for brain issues. Their findings to indicate that automated hybrid closed loop systems work really well and that better glucose control can actually improve brain structure and function in teens with type 1. I've reached out to this group and we're working on getting more information in a future episode. https://neurosciencenews.com/blood-sugar-brain-diabetes-21328/ XX Very early on here.. but an Indiana startup says they have a potentially game changing type 1 drug in development. In T1D, the body's immune system causes destruction of beta cells, and as a result, they eventually stop producing insulin. These researchers say their models show thy can take what were thought to be dead beta cells, which are actually sleeping beta cells, and increase their insulin secretion and, basically, get them back to a functional state." They're focusing on a calcium imbalance within the beta cell and designing molecules to correct that calcium imbalance, ultimately returning the pancreas to a healthy state. JDRF has given them a big grant for a two year project, hopefully getting them to clinical trials. https://www.insideindianabusiness.com/articles/startup-awarded-nearly-1m-to-advance-diabetes-drug XX People with type 2 diabetes might face a substantially increased risk of heart failure if they take ibuprofen or some other type of nonsteroidal anti-inflammatory drug (NSAID), accord to a new Danish study. Short-term NSAID use increased risk of hospitalization for heart failure by 43% in people with type 2 but no previous heart problems. This was a large but preliminary study presented at the European Society of Cardiology's annual meeting. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), t

Stacey's son spent the summer away at regular, non-diabetes sleepaway camp. 8 weeks managing all of his own care, with no remote monitoring. You had a lot of questions, including how he manages overnight lows: Benny is 17, he was diagnosed just before he turned two and, as usual, he has a lot to say. He had quite a few adventures at camp, but everything turned out okay. We get his take on independence, responsibility and a glimpse into how a teen with type 1 thinks. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! The top stories and headlines around the diabetes community this week include a new attempt to have fewer misdiagnoses of type 2 (when it's really type 1) diabetes, a new approval for Omnipod 5 down to two years old, a look at the endocrinologist shortage in the US, a milestone for Tandem and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX New effort to avoid the very common misdiagnosis of type 2 when it's actually type 1. JDRF and a a company called IQVIA are seeing if artificial intelligence can be used here. IQVIA used machine learning to look at data from individuals diagnosed with T2D and then, later, diagnosed with T1D within a specific time frame. The big problem, the company says, is that medical records are often incomplete and are compiled using different standards and formats. They call it a good starting point though. Earlier studies have shown that possibly 40-percent of adults with new onset type 1 are first misdiagnosed with type 2. https://www.jdrf.org/blog/2022/08/11/iqvia-algorithm-for-misdiagnoses/ XX New UK study about COVID, diabetes and kids.. shows there was an increase in new cases and in DKA. This was from March 2020 to February of 2021, compared to same time the previous year. This was a large study, looking back at cases across 49 sites. There was a 17% increase in new-onset diabetes from Year 1 to Year 2, mostly of type 1 diabetes. ED visits for DKA dropped by 31.9% during the pandemic year among patients with existing diabetes. There was a 43% increase in severity of new-onset disease from Year 1 to Year 2, with severe DKA increasing by 79% (P https://www.medscape.com/viewarticle/979381#:~:text=There%20was%20a%2017%25%20increase,by%2079%25%20(P%20%3C%20. XX Omipod 5 is now FDA approved for kids as young as two. Omnipod 5, the first tubeless automated insulin delivery (AID) system in the U.S., was originally cleared for use in individuals aged six and older in January 2022. That makes Omnipod 5 the only AID approved for the toddler set. Tandem's Control IQ ia approved down to age 6 and Medtronic 780G down to age 7 https://www.businesswire.com/news/home/20220822005158/en/Insulet-Announces-FDA-Clearance-of-Omnipod%C2%AE-5-for-Children-Aged-Two-Years-and-Older-with-Type-1-Diabetes XX Milestone from Tandem they say that in the first month since the new mobile bolus feature was released, users have delivered more than 1 million insulin boluses. The company said in a news release that it is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems. The company added that it is now available on approximately 30 different devices. https://www.drugdeliverybusiness.com/tandem-diabetes-app-insulin-bolus-million/ XX What looks like an editorial in a publication called Stability Health caught my eye. It's all about the shortage of endocrinologists in the US. Right now there are only 8-thousand in practice across the whole country. Endocrinologists receive the lowest compensation of all internal medicine (IM) specialties — lower even than practicing general internists — and 76–89% of medical students graduate with astronomical debt. Additionally, these clinicians often make themselves available outside of their office hours. But since this time may not be billable, it is often not supported in salaried compensation. Separately (but related), in 2016, 71% of entrants to the field of endocrinology were female. Due to America's long-standing gender wage gap, this may be a contributing factor in wage stagnation. Roughly 85% of Americans with diabetes rely on a general practitioner for their care. I'll link up the column so you can take a look. https://stabilityhealth.com/endocrinologist-shortage/?fbclid=IwAR0jx-nSiOL2UccmoJ9H74SnC6l3M5CCppecGcQ2t2M_zc7U-ydOj4JxfQ4#:~:text=Today%2C%2034.2%20million%20Americans%20are,currently%20practice%20in%20the%20U.S XX Update on one of the CGM smartwatches we've been keeping an eye on.. the K-Watch Glucose CGM watch is being tested by a French Company. They had their first clinical trials last year and got results this summer. the first run had a MARD of 29-percent.. brought down to a mu

Back to school can be one of the most stressful times for parents of kids with T1D and it's okay to admit that. This week, Anna Sabino, of Finding Smiles Coaching, a diabetes educator who lives with type 1, joins Stacey to help you out! We're going to go through 504s, school supplies, remote monitoring, last minute issues and set you up for long term success. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Anna, including a great special she has for parents and families right now: https://www.findingsmilescoaching.com/ ADA Safe at School: https://diabetes.org/tools-support/know-your-rights/safe-at-school-state-laws 504 plan examples: https://diabetes.org/tools-support/know-your-rights/safe-at-school-state-laws/written-care-plans/section-504-plan Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! The top stories and headlines around the diabetes community this week include: People on Medicare should see insulin prices capped, A look at whether the tuberculosis vaccine prevented Covid in people with type 1 diabetes, Tandem's CEO has some news about their tiny Mobi pump, students create non-invasive glucose monitoring, and some progress on smart insulin. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The Inflation Reduction act is now law.. and that means a big change for Medicare patients. Among other things, it limits insulin copays to $35 per month for Medicare Part D beneficiaries starting in 2023 and caps annual out-of-pocket cap on Part D prescription drugs at 2-thousand dollars starting in 2025. Medicare will also now have the ability to negotiate the costs of certain prescription drugs. Democrats say they will try to bring a stand alone proposal to ap the price of insulin for a broader population this fall. XXDid the Tuberculosis vaccine protect people with type 1 from Covid and other infectious diseases? Researchers at Harvard Medical School and Massachusetts General Hospital have published a new paper looking at the BCG or tuberculosis vaccine. In a double-blind, placebo-controlled study of patients with type 1 diabetes conducted at the start of the pandemic, before COVID vaccines were available, only 12.5 percent of placebo-treated individuals and 1 percent of BCG-treated individuals had confirmed COVID-19, yielding a vaccine effectiveness of 92 percent. The BCG-vaccinated group also displayed protective effects against other infectious diseases, including fewer symptoms, lesser severity and fewer infectious disease events per patient. No BCG-related systemic adverse events occurred. The participants in the COVID trial had previously enrolled in a clinical trial testing the effectiveness of the BCG vaccine for type 1 diabetes. Participants in the test group had received multiple vaccinations before the onset of the pandemic in early 2020. https://hms.harvard.edu/news/tb-drug-vs-covid XX Students at the American University in Cairo have developed a device that non-invasively measures blood glucose levels, winning first place in 2022 Johns Hopkins Healthcare Design Competition. The device uses near-infrared spectroscopy (speck-troh-sku-pee). It's called GlucoClip and there's also a mobile app. . The project took a year, with the team having designed a prototype and testing it on more than 100 people. Amazing that this took students less than a year.. we'll see if the large commercial companies can accomplish getting something like this to the marketplace. https://www.egyptindependent.com/auc-students-win-first-place-at-johns-hopkins-healthcare-design-competition-2022/ XX Interesting progress on glucose-responsive insulin, also called smart insulin. These researchers envision ultra-stable proteins containing a glucagon analog "stapled" to an insulin analog. Preliminary studies are moving along at Indiana University. As the name indicates, this would be insulin that only responds when there is too much glucose in the blood, making the risk of low blood sugar much less likely. Nice to see some options may be possible, last year Lilly bought Protomer Technologies which had smart insulin in pre-clinical development. https://diabetesresearchconnection.org/projects/fusion-protein/ XX New CEO over at Beta Bionics – the company behind the iLet Bionic Pancreas, currently in front of the FDA. Sean Saint will be the new CEO, Martha Goldberg Aronson was interim, we talked to her for the podcast a few months ago, will remain on the Beta Bionics Board of Directors. Saint is an engineer, entrepreneur, diabetes technologist and innovator, and lives with type 1. He started at Medtronic and ahs also been at Dexcom and Tandem. It was after working at all those diabetes companies that he developed type 1 as an adult.. and founded Companion Medical, maker of the InPen. Really interesting story and I hope he'll come on the podcast soon. https://www.globenewswire.com/news-release/2022/08/15/2498485/0/en/Beta-Bionics-Appoints-Sean-Saint-as-CEO-and-Board-M

You may know the Inflation Reduction Act best for being the latest time an insulin price measure was NOT voted through. But supporters say there's a lot here that will help patients save money, including those with diabetes. We talk with Sarah Kaminer Bourland, Legislative Director of Patient for Affordable Drugs Now. She explains what this new plan will mean for those on and not on Medicare, debunk some of the talking points you might have heard and look ahead to what could be next for insulin pricing. Share your story with P4AD: https://secure.everyaction.com/SvIaRhn3VEmVAkJ1ccQETA2 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Get caught up on the news and headlines around the diabetes community! The top stories in the last seven days: Senate Republicans nixed an insulin copay cap, but Democrats say they will revisit this issue in a few weeks, Dexcom pushed back their G7 timeline in the USA after the FDA asks for changes, once weekly basal insulin moves forward in trials. Plus, Beyond Type 1 is back in the NYC Marathon and much more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The copay cap on insulin may come back before the Senate in a few weeks. Senate Majority Leader Charles Schumer say he'll bring tht issue back up.. after Republicans blocked it in a sweeping climate, inflation and health care package passed by the Senate on Monday. Speaking on MSNBC's "The Rachel Maddow Show." Schumer said, "We're going to come back and make them vote on that again." Seven Republicans still voted with all 50 Democrats, three short of the 60 votes needed, and it is possible more Republicans would support it if it came up as a standalone measure. It's not clear if this would again be a copay cap or in fact a cap on the actual price of insulin for all, including the uninsured. https://thehill.com/policy/healthcare/3594003-schumer-senate-will-vote-again-on-35-insulin-cap-after-gop-blocked-it/ XX Dexcom is pushing back the timeline for a U.S. launch the G7. That's after the FDA raised questions about the device's software during a review. This has something to do with how the G7 and it's smartphone apps deliver alarms to users. Looks like maybe a limited release in the 4th quarter of this year and full rollout in 2023 if there aren't any other hiccups. As you likely know, the G7 is nearly 60-percent smaller than the G6, it's transmitter and sensor all in one and has a much shorter warmup period. It's been approved in Europe since March. https://www.fiercebiotech.com/medtech/dexcom-resubmit-g7-glucose-monitor-software-fda-review-pushing-back-us-launch XX One type of once-a-week basal insulin gets the go ahead to move forward with clinical trials in the US. Gan & Lee Pharmaceuticals says it's investigation drug called GZR4 is more stable with less day to day variation than once a day basal insulin. There are a few of these weekly insulins in trials, none yet approved. Gan & Lee is also doing trials of the drug in China where they are already a big player in the insulin market. https://www.ganlee.com/detail/668.html XX XX Good news for Senseonics, makers of the Eversense implantable CGM. Shares were up on second quarter earnings and future expectations. I don't generally report on stock market moves of diabetes companies, but the past few years have been a bit iffy for Senseonics and there was speculation on whether this CGM option might not be available in the US. They partnered with Ascensia Diabetes Care and got the six month approval for Eversense earlier this year. https://www.massdevice.com/senseonics-stock-q2-2022/ XX A new call for comments to the FDA but the deadline is TODAY august 15 at midnight eastern time. I'm going to read directly from a post by Joanne Milo in the CGM in the Cloud off topic group. Joanne's been a guest of the show and leads the loop and learn group – she writes. "We have until August 15, 2022 to provide comments on FDA changes to the way CGM display and alarm systems are regulated. This has implications for remote monitoring and automated insulin delivery systems, both commercial and DIY. We request your assistance in helping the FDA and device providers (FDA considers software for treatment of disease to be a device) understand the benefits of real-time CGM access and the risks we carry by not having ubiquitous real-time access to our diabetes device data. We hope you will choose to spend a moment to add your voice to the #WeAreNotWaiting chorus. They provide some text which I'll link up in the show notes as well as the links to this post and the FDA comment portal. https://www.regulations.gov/commenton/FDA-2018-N-1910-0047?fbclid=IwAR2WAtGl3vjTUonamNdlBtAu_pg2-xQOVy8bSqG2peLCUz2eq8R8OgLqtHQ https://www.facebook.com/groups/CGMITCOFFTOPIC XX The T1D Exchange Registry i

I started Diabetes Connections back in the summer of 2015. I'm not sure I had a number of episodes in mind when I kicked off the show, I just knew I wanted to make a podcast for and about the diabetes community. Thanks for tuning in all this time! For episode 500, I've turned hosting duties over to Cristina Frank, a TV news anchor who lives with type 1. We talk about how the episodes come together, what's worked (and what hasn't) and what I might add to the show going forward. We also think about how the community has changed and why the highest praise I could take for this show is that it's authentic. Thanks, all!! -Stacey Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Jeff Ryan has lived with type 1 for more than 50 years. But he also has what's called an essential tremor. Part of the treatment for that included using powerful magnets, which made thinking about diabetes tech.. a little different for Jeff. He talks about being diagnosed as a toddler in 1971, and how treatment for both his tremor and his type 1 have changed.. as well as the power of community for both conditions. He recently got his 50 year Joslin Medal and shares how a photo of him in front of a Christmas tree in 1971 played a role. That photo was a bit of a mystery to Jeff for a long time, since he was diagnosed in October. 2001 story about Jeff's brain surgery: https://www.webmd.com/brain/news/20010822/pacemaker-for-brain-effectively-stops-tremors This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News! The tops diabetes stories this week include: Australian scientists say they have a new way to restore insulin production using an existing and approved drug, Tandem rolls out bolus by phone for wider release and acquires Capillary Biomedical, an infusion set maker. Dexcom adds Spanish as a language option for the G6, a necklace is said to be able to monitor glucose levels and Netflix's Purple Hearts focuses on type 1 medical costs as a plot point. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Australian scientists say they have a new way to restore insulin production in pancreatic cells, using a drug that's already approved for use in humans. In lab experiments on pancreatic stem cells from donors with type 1 diabetes, the team was able to activate them to begin expressing insulin by exposing them to a drug compound known as GSK126. These cells don't normally produce insulin, but the drug let them functionally step into the shoes of the beta cells that had stopped working. In principle, a single course of this kind of drug over a few days could replace the need for regular insulin shots in diabetics. The new treatment would work much faster, within a matter of days, and without the need for surgery. But perhaps the biggest advantage is that GSK126 is already approved by the US FDA and elsewhere in the world as a treatment for cancer. Its safety profile is already being assessed in clinical trials, which could reduce hurdles down the road for its use against diabetes. That said, the scientists caution that it is still very early days. These experiments were conducted on cells in culture – not even in animals yet – so there's still plenty of work to do. Nevertheless, it remains an intriguing new possible tool. https://newatlas.com/medical/diabetes-breakthrough-insulin-production-existing-drug/ XX Couple of big announcements from Tandem Diabetes this week. They've widened the roll out of their Mobile Bolus feature, now open to all customers with in-warranty tslim x2 pumps and compatible smart phones. Approved earlier this year, it has been available for a few weeks to a small group of users. https://www.tandemdiabetes.com/products/software-apps/tconnect-mobile XX Tandem also announced it acquired infusion set developer Capillary Biomedical, an infusion set maker. To quote the press release: Capillary Biomedical's unique extended wear infusion set technology is currently in development and not commercially available. The company designed its SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability. Capillary Biomedical received FDA investigational device exemption for the platform in January of this year. https://www.drugdeliverybusiness.com/tandem-diabetes-acquires-capillary-biomedical-infusion/ XX Dexcom is launching their G6 mobile app in Spanish. It is estimated that 11.8% of U.S. Latino adults have diagnosed diabetes. Dexcom says, " "Launching the Dexcom G6 app in Spanish is a positive step toward improving health equity for individuals with diabetes who primarily speak Spanish." To access the Dexcom G6 mobile app in Spanish, users need to install the latest version of the app and set their compatible iOS (v1.10.1) or Android (v1.10.0) smartphone* language to Spanish (any dialect/region). The app will automatically display in Spanish as long as the phone language is set to Spanish. XX Big issue for a diabetes app in the UK. CamAps FX is an automated insulin delivery system that works with Dexcom and Tandem. But Google has blocked it from the Play Store and won't let it send text message alerts. Camdiab, the company behind it, is having to send the messages via another service and pay for each one individually. Google said it doesn't allow any apps, other than the designated text message app on a device, to send SMS messages. CamAps FX spent 15 years in development by experts at Cambridge University and was the first system of its kind to be recommended by the NHS for use by children from the age of one, and pregnant people. We'll see if the court of public opinion has

Sebastien Sasseville recently completed The Race Across America, a grueling 3-thousand miles coast to coast cycling event that riders must complete in only 12 days. That means pushing through not just diabetes, Sasseville lives with type 1, but also eating on the bike and sleeping just a few hours at a time. Sasseville has been an ultra athlete for two decades now. We get more details about this race, why he wanted to do it and how he managed type 1 throughout. More on Sassville here: https://sebinspire.com/en/ This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Top stories In the News this week, United Healthcare announces changes to how they cover insulin for some, a new study looks at CGM use in people with type 2 over the age of 65, another company begins islet cell clinical trials, a new tool to treat diabetic neuropathy pain, gestational diabetes is on the rise, and more. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story.. United Healthcare says it will have no "out of pocket" expenses for insulin starting January first. It's doing the same for other critical drugs like glucagon, epinephrine and albuterol. Looking into this a bit more, though, it's not the boon it first seems. This only covers certain eligible patients. Stat news says about a quarter of United Healthcare's patients will qualify but I saw a few commentators say it could actually be less than 5-percent. UnitedHealth Group shared that it earned $5.1 billion in profit for the second quarter of 2022. https://kstp.com/kstp-news/top-news/united-healthcare-says-no-out-of-pocket-expenses-for-insulin/ XX Not too surprising but a good study about people with type 2 using CGMs. This was for people using basal insulin only and over 65 years old. They found when given a CGM, their A1Cs went down an average of 1 full point with fewer lows. These are the kinds of studies that may seem obvious to us but that are needed to show insurers they need to cover. https://www.liebertpub.com/doi/10.1089/dia.2021.0494 XX New device approved to treat pain associated with diabetic peripheral neuropathy. The DyAnsys' First Relief system is set behind the ear – its an adhesive, nothing surgical. It features three small, acupuncturelike needles that reach through the skin behind the ear to access the nervous system. Once in place, the device continuously emits low-level electrical pulses over the course of several days at a time; the FDA cleared the system for repeated treatments spanning up to eight weeks. https://www.fiercebiotech.com/medtech/fda-clears-wearable-neurostimulator-dyansys-treat-pain-diabetic-nerve-damage XX Another company having success with islet cell transplants. ProtoKinetix announced they're completely safety objectives and will start phase 1 clinical trials of their molecule PKX-001. Not much to report here yet, but I didn't want to news of the Vertex/Viactye merger to over shadow that there are other efforts going on here. https://www.businesswire.com/news/home/20220720005086/en/ProtoKinetix-Successfully-Completes-Phase-1-Clinical-Trials-for-the-Treatment-of-Type-1-Diabetes-in-Islet-Cell-Transplants XX Roche and Insulet settle their lawsuit.. this was a patent issue and both companies were suing each other. Insulet will give Roche 20-million dollars and Roche has agreed not to sue Insulet for five years. This was set to go to trial next week. https://seekingalpha.com/news/3855728-insulet-to-pay-20m-to-settle-patent-lawsuit XX Gestational diabetes is on the rise, climbing 30% between 2016 and 2020, according to a new study by the Centers for Disease Control and Prevention.The CDC analysis showed that cases increased 13% during the first year of the pandemic alone, a much larger spike than the previous annual increases of about 5%. Experts say that the sharp increase during Covid may be because the disease accelerated people's adoption of a sedentary lifestyle and led to pandemic-related physical and emotional stress. experts are concerned outcomes in 2021 may be worse, when Covid hit harder. If anything, the authors and experts said, the new finding is likely an undercount. Relying on birth certificate data, which the CDC study did, can miss cases that are not captured by a physician on those forms. "If you think about it, somebody who's doing 20 deliveries in a night, or ten deliveries in a night, is just kind of trying to get those reports and certificates out there," said Morgan. "They're not paying as much attention to some of those details." https://www.statnews.com/2022/07/20/as-diabetes-during-pregnancy-grows-more-common-experts-point-to-a-need-for-preventive-care/ XX Right back to the news in a moment but first As I mentioned, The T1D Excha

When you're thinking about new diabetes technology, sometimes your endo is right there with you, keeping up on the latest & greatest. But if they're not, a new resource could help. Diabetes Wise Pro includes more than just pump and CGM specs. Stacey talks to Dr. Korey Hood, the co founder of DiabetesWise, a website that launched a few years ago to help consumers make more informed decisions around diabetes tech. We'll talk about why they launched this new effort, who it's for and how it could even change the prescription process. More info https://providers.diabeteswise.org/#/ This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out our previous interviews with Dr. Hood: https://diabetes-connections.com/?s=korey+hood Check out the T1D exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem's new mobile bolus feature, One Drop shows a "health sensor" on its website, a study shows that screening for type 1 at very young ages could help detect most cases and much more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story this week, Vertex buys Viacyte! For context, Vertex is the company that got all the headlines last fall – big article in the New York Times for a stem cell therapy that brought one person with type 1 off insulin completely. The FDA put them on hold but lifted that just last week. Vertex previously acquired Dr. Doug Melton's Semma. Viactye is the company featured in the documentary "The Human Trial" - they're using CRISPR technology to keep the body from rejecting their stem cells. Both companies technology does NOT require immunosuppressive drugs and both say they are working toward a functional cure. Some experts are saying this will speed up that effort while critics worry that it eliminates the competitive aspect of the race. Sernova is still one separate company that has shown stem cell therapy can work.. I've got requests out to Viacyte to talk to us about all of this, so stay tuned. https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-viacyte-goal-accelerating-its-potentially?fbclid=IwAR15qlFSBsBR89blzXymyIGL3tW5C64QtdHpwq7a5fdjmv2q6JmfoTIpm-k XX If we widely screened kids for type 1 at certain ages, a new study suggests, it would identify most of those who go on to develop it by their teen years. These researchers looked at screening for the type 1 autoantibodies at ages 2 and 6. This included nearly 25-thousand children from Europe and US. One issue in this study, funded by JDRF, all the participants in the combined dataset had genetic risk factors for the disease or a relative with type 1 diabetes, in whom performance is expected to be higher. It also included almost exclusively kids of northern European ancestry. https://www.medscape.com/viewarticle/976992 XX Tandem bolus by phone is slowly rolling out. This week, the T:Connect app was updated in the The t:connect app was updated and emails started arriving for those notified they were part of the early release groups. I did see some reports of people not yet getting the email but seeing the update in their portal so be sure and check. Mobile Bolus is reportedly available for those using Control IQ and Basal IQ. It's worth noting that for those outside the US there really is no timeline, but Tandem has previously said they're going to replace t:connect with a new system that will debut outside the US first. By the way, I got my email this morning, but Benny is still at camp for three more weeks so it'll be a bit before we do the update! XX Interesting look at teens and young adults with type 1.. the early morning psychosocial state may explain a proportion of their daily variance in time in range. The study included 88 participants aged between 14 and 26 years, 56-percent of whom were women. This is tough to quantify but they had the participants complete an engagement prediction survey and set a diabetes management goal for the day when they woke up, and also completed an evening survey. These questions were about mood, motivation, control beliefs, social support, stress, general health, self-esteem, and perceived need for assistance. Of note, lower morning glucose levels correlated with measures of good sleep, high motivation, and good health, whereas higher morning glucose levels were associated with illness and feeling the need for support. https://www.medwirenews.com/diabetes/morning-mindset-daily-glucose-fluctuations-young-people-diabetes/23255450 XX Good catch by our friend Nerdabetic over on Twitter.. One Drop plans to enter what they're calling the continuous health sensing market with a daily disposable, minimally invasive biosensor in development. They say this is designed to provide greater flexibility and insights for people living wit

It's that time of year - diabetes camps are in full swing. As remote monitoring technology changes, many camps are adapting as well. There's a new system that lets camp staff monitor everyone's CGM, all at once. That's Sarah Gleich, executive director of the Nevada California Diabetes Association. We'll find out more about what's called CampViews, where it's already in place, how it's going and whether it'll change diabetes camp for good. This technology could also make a big difference for hospitals, nursing homes and other health facilities. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Her daughter was diagnosed during the first year of COVID.. now Katie Roseborough is looking to help other moms by sharing her story. Katie's started a podcast; she talks about why and shares stories about her family's experience. She has three kids, only one with type 1. More about Katie here https://www.sugarmamaspodcast.com/ Book presales are open! "STILL The World's Worst Diabetes Mom" will be out this fall. Order now and use promo code "Earlybird" to save $5! https://diabetes-connections.com/book-store/ You can also save $5 on the first "World's Worst Diabetes Mom" at that link, just use "Earlybird" at checkout. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Top stories in the news this week: researchers are testing an injection to help prevent type 1 diabetes while not harming the immune system, a new study looks at older adults and CGM use, help for pharmacists when it comes to prescribing CGM and a new group takes over the Lilly Diabetes Journey Award Medals. Plus, amazing feats of endurance from ultra athletes with type 1 diabetes. Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Interesting new study looking at preventing type 1. The drug, currently known as IMCY-0098, blocks the immune system response that is thought to be the trigger. Very early on here, the Oxford scientists who are part of the study say it will likely be at least ten years before they'll be able to bring it to market, if it works. One of the most promising aspects is that the injection seems to only target production of cells that damage the immune system, so it doesn't seem to affect the body's ability to protect itself against other infections. https://www.dailymail.co.uk/health/article-10952755/Type-1-diabetes-stopped-strikes-thanks-simple-jab.html XX No surprise but glad this is being looked at. Older adults with type 1 diabetes using CGMs for the first time had lower A1Cs AND fewer lows. This study called WISDM - Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) followed adults over 60 for six months. These researchers say the benefits of CGM combined with recently improved Medicare coverage should serve to increase adoption of CGM as standard of care in all adult populations, especially older people who are at increased risk of hypoglycemia. https://www.healio.com/news/endocrinology/20220627/cgm-improves-time-in-range-reduces-hba1c-for-older-adults-with-type-1-diabetes XX New resource thanks to the Helmsley Trust. This is for pharmacists and it's hoped it will expand patient access to CGMs. The release says Involving pharmacists in providing access is especially important for rural communities where they may be the most reachable healthcare professionals given the lack of diabetes specialists across the U.S. The guide was developed by the American Pharmacists Association and its Foundation http://ow.ly/zZ3c50Jz20f XX Looks like the Lilly Diabetes Journey Award Medals are getting a second life. As we reported back in January, after nearly 50 years, Lilly decided to end the program which gives a small medal for 10,25, 50 and 75 years of living with diabetes. The group Children with Diabetes – best known for putting on the Friends for Life Conference has taken it over. They'll now be called the CWD Journey Awards. You don't have to attend one of their conferences to get one and there is no cost. I'll give you the link to learn more and order one. XX The vets and keepers at the Royal Zoological Society of Scotland (RZSS) diagnosed the first reported case of diabetes in a giant anteater. Stephanie Mota, resident veterinary surgeon at RZSS said: "Keepers first discovered something was wrong when Nala was losing weight despite eating the same amount, or sometimes even more, than usual. "We carried out a full health check under general anaesthetic, running lots of tests and found that Nala has type 1 diabetes." While the condition is known to occur in domestic cats, dogs and in tamanduas (Tuh-man-doo-uhs) in the wild, no other cases have been reported in giant anteaters. BTW a Tu-man-doo-uh is a smaller anteater and I spent far too much time today watching videos of them because I had never head of them and they are amazing. Dexcom donated the CGM to the Zoo's charity. The story I read here says. Due to her lovely personality, Nala is the ideal candidate for this technology which helps us, and her amazing team of keepers, manage her condition in the best possible way. https://www.edinburghnews.scotsman.com/news/people/edinburgh-zoo-monitor-uks-first-diabetic-giant-anteater-with-blood-glucose-monitor-usually-used-on-humans-3749422 XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research stud

This summer we get a behind the scenes look at the evolution of stem cells as a functional cure for type 1. The Human Trial is new documentary that follows the process and the filmmakers are incredibly optimistic about what they've seen. Co-director Lisa Hepner lives with type 1. She's says she's knows to be careful about "the cure in five years' kind of statements but is convinced this is the real deal. We'll talk about the the film, the process, the science and a lot more. Listen to our first interview with Lisa Hepner from 2016 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News.." got a few minutes? Get caught up! Top stories this week: The US Senate may have a bipartisan plan to lower the price of insulin for the insured, nasal insulin is tested to reduce the risk of Alzheimer's in people with diabetes, two interesting studies about sleep and diabetes, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Two Senators have unveiled legislation aimed at lowering the cost of insulin, but not for the uninsured. This is a bipartisan bill that would lower patietn's cost to 35-dollars a month, for those with commercial insurance and on Medicare. It would eliminate the rebates drug companies pay to negotiators known as pharmacy benefit managers if the drug company kept the overall price of insulin below a certain level. Democrats are also in the midst of talks on a party-line package on President Biden's economic agenda that would likely include reductions in insulin costs as well as broader measures aimed at lowering drug prices, which could complicate any push for a stand-alone insulin measure. This change has enormous support among Americans, but can't seem to get any real traction in Washington despite who's in power. We'll see what happens.. https://thehill.com/policy/healthcare/3531954-bipartisan-pair-of-senators-unveils-bill-to-lower-insulin-costs/ XX Nasal insulin doesn't look like it works too well on diabetes, but a new study shows it may help to slow age related mental decline. This study found that after 12 months of once daily intranasal insulin, people with diabetes in the study performed better on cognitive tests than those diabetics in the placebo group. The non-diabetic group receiving the intranasal insulin also displayed improvements on decision making and verbal memory tests compared to non-diabetics in the placebo group. The biggest improvements in the non-diabetic group were seen in those subjects who started the trial in a prediabetic state. This suggests the treatment may be most effective at slowing cognitive decline in either diabetics or those with prediabetes. https://newatlas.com/health-wellbeing/insulin-nasal-spray-cognitive-decline-dementia-clinical-trial/ XX Go to sleep, and don't breathe too much. Researchers in the U.K. will test hypoxia to treat type 2 diabetes. Hypoxia is a state where the body does not receive sufficient amounts of oxygen. Multiple studies have shown that hypoxia improves blood sugar levels and aids in weight loss. Although scientists do not fully understand how this works, it is suggested that hypoxia burns more calories in the body, resulting in lower appetites in individuals. These researchers want to recruit volunteers so they can figure out why. Each volunteer will be provided with a sleeping tent in which they have to sleep – at home - for 10-day periods on two separate occasions. For one of they nights, they oxygen levels will be set to 15 percent. That sounds ridiculous, but, the air we breathe right now is only about 21% oxygen. 15-percent is pretty typical for find at high altitudes or inside an airplane. https://interestingengineering.com/lose-weight-while-asleep XX Another look at sleeping and type 2.. an exposure to light may increase the risk. Big sleep study at Northwestern University found that exposure to any amount of light during the sleep period was correlated with the higher prevalence of diabetes, obesity and hypertension in both older men and women. A study published earlier this year by the same team found for healthy adults in their 20s. Sleeping for only one night with a dim light, such as a TV set with the sound off, raised the blood sugar and heart rate. An elevated heart rate at night has been shown in prior studies to be a risk factor for future heart disease and early death, while higher blood sugar levels are a sign of insulin resistance, which can ultimately lead to type 2 diabetes. Instead of pulling people into a sleep lab, the new study used a real-world setting. Researchers gave 552 men and women between the ages of 63 and 84 an actigraph, a small device worn like a wristwatch that measures sleep cycles, average movement and light exposure. Fewer than half of the adults in the study got five hours

Wearing an insulin pump can be a huge help when it comes to managing diabetes, but finding a place to put it can be difficult. Women's clothing in particular, isn't great for storing stuff. Erin Calhoun-Dulaney has lived with type 1 for 40 years and she finally got fed up enough to create her own product. We'll talk about Skirt my Pump, her experience with T1D and her career as a Hollywood publicist. Stacey also has information about Tandem's Mobile Bolus limited roll out. Click here to find out more and sign up. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News.." got a few minutes? Get caught up! Top stories this week: Tandem Diabetes announces a limited launch of their mobile bolus feature (signup below), researchers look at how Basaglar stacks up, new guidelines for diabetes in the hospital, a T1D extreme athlete bikes across the USA and more Learn about the T1D Exchange! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Tandem's mobile bolus feature is in limited release. Approved earlier this year, they've released the feature to a very small number of users and are expecting a wider, still limited, release in the next few weeks. This is the feature that allows you to bolus by phone and use the t-connect app to see pump data on your phone as well. It's not full pump control via phone, but it's a big step forward in terms of convenience for users and for Tandem' next product, the MOBI pump – which won't have a screen and will have full phone control. I'm asking Tandem to come on the show and share more about the features and how it works. It's interesting that you can't dismiss alerts and alarms from the app and must do so on the pump itself. I'll link up the site you need to sign up for the limited release. You will need to update the software on your tslim x2 pump and take some additional online training. This is US only. https://www.tandemdiabetes.com/landing-pages/remote-bolus XX The Eversense E3 gets European approval. This is a partnership between Ascensia diabetes care and Senseonics. The E3 is the six month version of the implantable CGM system. It's also approved for insulin treatment decisions, which is a switch from the XL version already available in Europe. The E3 was approved in the US earlier this year and should be distributed in Europe in the fall. https://finance.yahoo.com/news/ascensia-diabetes-care-announces-european-060000125.html XX XX New guidelines for treating diabetes in the hospital. This is from the Endocrine Society, which last updated their guidelines ten years ago. New this time around, hospital use of continuous glucose monitoring and insulin pump therapy, providing inpatient diabetes education as part of a comprehensive diabetes discharge-planning process, use of noninsulin glucose-lowering therapies, and more. Adult patients with diabetes or newly recognized hyperglycemia account for greater than 30% of noncritically ill hospitalized patients. https://www.clinicaladvisor.com/home/topics/endocrinology-information-center/endocrine-society-issues-new-guidelines-for-hospitalized-patients-with-diabetes/ XX Works just as well and costs less.. that's the upshot of a new study on Basaglar, the copycat insulin to Lantus when it comes to type 2 diabetes. The findings come from 14 commercial health plans and Medicare Advantage plans. Basaglar was approved as a biosimilar insulin glargine by the US Food and Drug Administration in 2015. This was a large study of thousands of patients and also showed that there was better adherence to Basaglar, no reason for that was given, but it could be the lower cost. https://www.medscape.com/viewarticle/975440 XX Right back to the news in a moment but first As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX Very early but Swedish researchers have now identified a molecule that helps stimulate the growth of new insulin-producing cells, and uncovered how it works. These researchers looked at a molecule known as CID661578 and found that it binds to a protein called MNK2. In doing so, i

Big news from Sernova, one of the companies hoping that implantable stem cells will be a functional cure for diabetes. They recently announced that the first person in their trials with type 1 is completely off injected or infused insulin – and is making their own. Stacey talks to Dr. Philip Toleikis, Sernova's president and CEO. He explains how their process differs from some of the other companies looking at stem cells, talks about their partnerships and shares more about the patients doing well in this clinical trial. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's "In the News.." got a few minutes? Get caught up! Top stories this week: The Federal Trade Commission probes the prescription drug middleman industry, once a week basal insulin moves forward, DIY insuln dosing systems get a thumbs up at ADA Scientific Sessions, Sernova's stem cell system releases great findings and more! Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry.. requiring the six largest pharmacy benefit managers to provide information and records. They're looking at PBMs such as CVS Caremark; Express Scripts, Inc.; OptumRx, Inc.; Humana Inc and more. The largest PBMs are now vertically integrated with the largest health insurance companies and wholly owned mail order and specialty pharmacies. In these roles, pharmacy benefit managers often have enormous influence on which drugs are prescribed to patients, which pharmacies patients can use, and how much patients ultimately pay at the pharmacy counter. https://www.ftc.gov/news-events/news/press-releases/2022/06/ftc-launches-inquiry-prescription-drug-middlemen-industry?utm_campaign=https://www.ftc.gov/news-&utm_content=1654622484&utm_medium=social&utm_source=twitter XX Confirming what many of you have known for years.. an open-source automated insulin delivery system -- also known as a do-it-yourself system -- was both safe and effective for patients with type 1 diabetes. This is from the CREATE trial, designed to test DIY system, presented for the first time at the ADA Scientific Sessions. This system was made up of the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone, paired with the DANA-i insulin pump and Dexcom G6 continuous glucose monitor. The researchers previously published additional information in the Journal of Diabetes & Metabolic Disorders. https://www.medpagetoday.com/meetingcoverage/ada/99109 XX Stem cell study showing great results. Sernova says the first three patients of six total continue to be insulin independent following treatment. One of the patients has been insulin-free for more than two years, while the other two have been free of the need for medication injections for six months and three months, respectively. At this point, the other three patients in the study have not had the device long enough to determine measurable results. The first three all have A1Cs in a normal, nondiabetic range. Sernova's Cell Pouch is an implantable device that releases the primary donor islets. The device is implanted under the skin in a minimally-invasive procedure. We're talking to Sernova for next week's show; long way to go here but another good result for stem cells. https://www.biospace.com/article/sernova-cell-pouch-device-keeps-type-1-diabetes-patient-insulin-free-for-two-years/ XX Getting closer to once-a-week basal insulin. New study says Novo Nordisk insulin icodec achieved better results than Lantus in some aspects of the study and that overall it was – this is interesting wording – non-inferior. Another previous study showed it also matched well to Tresiba, but that Tresiba caused fewer lows than the once-weekly basal. This study was about type 2 diabetes but insuln icodec is in other trials for people with type 1. https://www.biospace.com/article/novo-nordisk-scores-phase-iii-insulin-win-strengthening-market-position/ XX New partnership between Diabeloop – which makes an automated insulin algorithm - and SOOIL which makes pumps. These are two French companies that have been working together since 2020 but this new announcement was delayed by COVID. They want to bring the product – Diabeloop's DBLG-1 I controller and SOOIL's Dana ACE Pump to the US, Europe and Korea. https://www.drugdeliverybusiness.com/diabeloop-sooil-automated-insulin-diabetes/ XX Civica continues to move ahead with the development of its affordable insulins. They've announced they'll partner with the German company Profil for the clinical trials. Civica plans to set a maximum recommended price to

Dexcom CEO Kevin Sayer joins Stacey from the American Diabetes Association's Scientific Sessions with new G7 information, a response to Abbott's Libre 3 approval, addressing rumors about acquiring another diabetes company and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

Got a few minutes? Get caught up on the top diabetes stories and headlines of the past week. The FDA approves Abbott's Freestyle Libre, Dexcom addresses reports it may buy Insulet, Ozempic becomes a TikTok trend, Diabetes Scholarships for college and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, FreeStye Libre 3 gets FDA approval. This is a 14 -day CGM, Abbot says it's smaller and thinner, about the size of two pennies stacked up. Abbott also claims Libre 3 is the most accurate 14-day CGM based on new results. It's worth noting that there isn't another 14-day CGM on the market.. Dexcom is ten days and the upcoming G7 seems to have similar accuracy. However, Libre is less expensive and they say there will be no price increase for this new model. Libre has had iCGM designation since the Libre 2 – but the FDA says it's still not allowed for use with automated insulin delivery systems. I've asked to speak with Abbott and we'll find out more about why that is and what the company plans to do if it can't integrate with insulin pumps in the US. XX Meanwhile, Dexcom pushes back on talk that it was interested in acquiring Insulet. Here's part of the quote: It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change." I'm set to talk to Dexcom's CEO at ADA and I'll definitely ask him about this, even though they say they won't comment further. I do think it's interesting they use the word "merger" and not also "acquisition" – but the stock market seems to believe them. Dexcom went up on the news. XX New information could link environmental pollution to type 1. New study from Norway says even low concentrations of such pollutants can result in cells producing less insulin. New cases in Norway have doubled in children and teens since the 1970s. This study also included samples from American kids. Overall, the researchers found a larger proportion of those with type 1 diabetes these pollutants in their blood. They also found when mice were exposed to the pollutants, insulin production went down. https://www.news-medical.net/news/20220530/Environmental-pollutants-may-be-the-reason-behind-development-of-type-1-diabetes.aspx XX Whey protein may be the next big thing for people with type 2. Drinking a pre-made shot before meals with a low dose of whey protein seems to help better control blood glucose levels. In this study, people went about their daily lives with no changes but the whey drink. Then they spent a week with no whey, all while wearing a CGM. On average, people had two hours additional per day of normal blood sugar levels compared to the week they skipped the protein drink. The researchers believe the whey slows down food in the digestive system and also stimulate hormones than help keep glucose from rising. This was a small study, but you can bet you'll be hearing a lot more follow up.. it's a simple and promising treatment. https://scitechdaily.com/just-a-small-amount-of-protein-supplement-helps-control-type-2-diabetes/ XX At least at one hospital, the pandemic showed the telemedicine and CGM use can make a big difference in kids with type 1. For the study published in BMC Pediatrics, these researchers used data from Children's Medical Center Dallas . While the number of office visits among patients decreased during the pandemic, there was no effect on disease management in this group – both glucose control and hospitalization rates were unchanged. However, the results highlighted existing disparities among patients in minority and low-income demographics. Both before and during the pandemic, Black and Hispanic patients and those without commercial insurance had worse glucose control and hi

Diabetes camp is great, but what if there were a program to take teens with type 1 on a more adventurous journey? A new, international travel program to foster confidence and independence is in the works. Savannah Johnson is the founder of Type 1 Way Ticket. Diagnosed as a toddler, she says travel as an adult changed her life. We'll find out more about this new adventure travel program, what parents and teens can expect. More about Type 1 Way Ticket Go Fund Me Page here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! Got a few minutes? Get caught up! Top stories this week: Dexcom is reportedly in talks to buy Omnipod, Abbott & Dexcom sue and countersue each other over patents, new study showing people with type 1 diabetes are living longer, a JDRF advocate climbs Mt Everest, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story this week is still developing.. but Bloomberg reports that Dexcom is in talks to acquire Insulet, the makers of Omnipod. Neither company has commented publicly on the report. Bloombeg says, "Talks between the companies are ongoing and an agreement could be reached in the coming weeks, said the people, who asked not to be identified because the information is private. Discussions could still be delayed or fall apart, the people said." Insulet's stock has gone up and Dexcom's has gone down. These companies already have an agreement in which the Omnipod and Dexcom CGMs communicate.. Dexcom also has an agreement with Tandem and some other companies – those aren't expected to change in the short term, but there are a lot more questions than answers about this report. I'm scheduled to talk to Dexcom's CEO in early June and we'll continue to follow this story. https://www.bloomberg.com/news/articles/2022-05-23/dexcom-is-said-in-talks-to-acquire-device-firm-insulet XX Meanwhile, Dexcom and Abbott are currently going head-to-head over twelve separate patents covering their respective CGMs. Both companies are launching newer products soon, with the Dexcom G7 and Freestyle Libre 3 already available in Germany. Dexcom first sued in 2021.. Abbot then countersued. A UK High Court will hold three separate technical trials, planned for December 2022, April 2023 and July 2023. https://www.juve-patent.com/news-and-stories/cases/dexcom-and-abbotts-fight-over-glucose-monitoring-patents-intensifies-in-europe/ XX People with type 1 diabetes are living longer according to a new study based on data from Australia, Denmark, Latvia, Scotland, Spain, and the United States. The years analyzed varied by country, but overall, they cover 2000 to 2016 and include 1.5 million person-years. The data show that country-by-country annual changes in age- and sex-standardized all-cause mortality among people with T1D dropped by between 2% and nearly 6% over the study period. The risk of dying was still higher than in people without type 1, mostly because of diabetes complications. https://www.ajmc.com/view/all-cause-mortality-falling-among-people-with-type-1-diabetes XX A new study finds that herpes virus may contribute increased risk of type 2 diabetes. Herpes viruses are one of the most common viruses in humans, with 8 types currently known. Any of these can cause lifelong latent infections after an initial, usually mild or asymptomatic primary infection. Until recently, viruses had only been proposed as a potential trigger for the development of type 1 diabetes. This study was based on health data from nearly 2000 people, men and women, in Germany. The researchers found that herpes viruses consistently and complementarily contributed to the development of prediabetes and diabetes, even after accounting for sex, age, BMI, education, smoking, physical activity, parental diabetes, hypertension, lipid levels, insulin resistance, and fasting glucose. https://www.pharmacytimes.com/view/study-herpesvirus-infection-may-increase-risk-of-diabetes XX This one sounds kind of odd, but a one-time diabetes treatment may lower average blood sugar and improve long-term insulin resistance and pancreatic function. The company is Fractyl, the treamtment is an outpatient proceure that applies heat to the intestinal walls to – quote – strip out and reset the mucosal lining, which can thicken over years from dietary fats, sugars and other foods. Fractyl believes this thickening contributes to the insulin resistance seen in Type 2 diabetes. The device has breakthrough FDA designation, but no approval yet. It is approved in Europe. https://www.fiercebiotech.com/medtech/fractyl-shows-its-intestine-resurfacing-device-

Mike Joyce is out there – somewhere – on the Pacific Crest Trail. He set out a couple of days before this episode airs, on a 2600 mile long distance hike. It's part of his attempt to complete what's called the Triple Crown of Hiking. He's already done the Appalachian Trail and the Continental Divide trail. Only 535 people have completed the Triple Crown. Mike lives with type 1 and he'll share how he went from pretty sedentary to long distance hiker and how he manages his diabetes on these incredibly long and challenging hikes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Follow Mike on Instagram Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's in the news! Got a few minutes? Get caught up! Top stories this week: new research that keeps beta cells safer after transplant, a new drug for type 2 also shows weight loss success, the makers of Afrezza buy a simple patch pump, Beyond Type 1 tackles mental health and diabetes and lots more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, another approach to beta cell encapsulation. There are a few methods being tested to protect the transplanted cells from the body's immune system. A new and promising one seems to be a new biomaterial in the form of microgel beads. This study was in mice only but after three months the beta cells survived and maintained blood sugar levels with no rejection drugs. Interestingly, this study put the cells into the omentum, not the liver as is apparently the usual spot. I never heard of the omentum.. in case you haven't, it's a layer of tissue connecting the stomach with the other abdominal organs. It's non-vital so it's safer if any complications take place. No word on when human trials might begin here. https://newatlas.com/medical/microgel-beads-safer-path-cell-transplants-treat-diabetes/ XX FDA approval for a new injection for type 2 diabetes called Mounjaro. It's made by Eli Illy and is shown to lower blood sugar and can help patients lose weight. Existing medicines target a hormone called the glucagon-like peptide-1 that is involved in the control of blood sugar. But Mounjaro targets a second hormone, the glucose-dependent insulinotropic polypeptide, as well. It is the first medicine to target both. While not yet approved as an obesity treatment, it's performed very well in clinical trials for weight loss. One study showed it helped patients lose an average of 16 to 22 percent of their weight: That's on par with bariatric surgery https://www.statnews.com/2022/05/13/fda-approves-lilly-diabetes-drug-that-analysts-expect-to-be-a-big-seller/ XX Big deal for MannKind, the makers of Afrezza inhalable insulin. They're acquiring Zealand Pharma's wearable V-Go Insulin Delivery Device. The V-Go is a patch pump that's meant for people with type 2 – it delivers basal insulin at a set rate all day long and can give boluses only in increments of 2 units of insulin at a time, up to 36 units in 24 hours. The deal is expected to close by the end of the month. https://www.mddionline.com/diabetes/mannkind-acquires-wearable-insulin-device-zealand-pharma XX Young adults who were at risk of food insecurity had an increased incidence of diabetes 10 years later, according to the results of a study from Washington State University. Although previous research has associated food insecurity with a range of health issues, this study showed a connection over time, which could indicate a causal relationship. The investigators could not identify the exact reason for this connection, previous research has shown that food-insecure households often have diets with lower nutritional values. The study results did not indicate differences among ethnicities or races, but they also said that a limitation of the study was the number of minorities in the sample, which could be too low to show a pattern, according to investigators. The investigators plan to evaluate food insecurity risk and health issues within American Indian and Alaska Native and American Indian populations, which they said are often left out of annual reports on food insecurity. XX Beyond Type 1 has a new mental health portal.. announced as part of this Mental Health Awareness Month. The global nonprofit is partnering with BetterHelp to provide affordable mental health resources and services to its online community with two weeks of free, professional online therapy. Beyond Type 1 will continue to expand the resources available on the site.. it's not just for this month. https://beyondtype1.org/mental-health/. XX Another entry into the quest to find a non-invasive way to monitor glucose. Movano Inc reports they have – quote - successfully validated the functionality of its proprietary and patented system-on-a-chip. T

We've got an update from Beta Bionics, makers of the iLet pump. This is the system that, among many other things, requires very little input from the user. They're hoping this makes it accessible for more people. Stacey talks to to interim CEO Martha Goldberg Aronson. She shares more information about recent studies regarding the Ilet, news about their submission to the FDA and a look into the future for this long-awaited piece of technology. More about Beta Bionics This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Top stories this week: racial disparities in treatment for kids with type 1, new study looks at oral insulin for type 2, nanoparticles tested to prevent diabetes and why is there a Squishmallow toy being marketed as having T1D? That and a lot more. Full transcript and links to sources below. Learn more about the T1D Exchange Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, Black children with type 1 diabetes experience disparities in health outcomes compared with other racial and ethnic groups with similar neighborhood opportunity profiles. That's according to a study published in the Journal of the American Medical Association Network Open. This was a very big study – more than 70-thousand patient encounters under the age of 21 from 2009 to 2018. They looked at something called the Child Opportunity Index. This It combines data from neighborhood-level indicators, like good schools, parks and playgrounds, clear air and safe housing. They found that the probability of readmission within a year was significantly higher among Black children with a very low COI category versus Hispanic children and White children at the same COI category. These researchers say doctors and educators need to be aware and include interventions that target racial disparities. https://www.physiciansweekly.com/outcomes-worse-for-children-with-type-1-diabetes-who-are-black XX New research suggests the people of certain racial ethnic groups should be screened for diabetes at lower body mass index than white people. A recommendation that contradicts recent guidelines from the United States Preventive Services Task Force. At a time when a lot of medicine is trying to rid itself of race-based tools this could be tricky.. but these researchers say that using a one-size-fits-all approach to screening, when diabetes is two to four times more prevalent and more deadly in Black, Hispanic, and Asian Americans, is likely to result in underdiagnosis of the disease, and widen health gaps. https://www.statnews.com/2022/05/09/race-ethnicity-bmi-diabetes-screening/ XX New partnership between JDRF, Yale University and a company called NexImmune. That company has something called Artificial Immune Modulation nanoparticles and the idea here is to if that could work with Teplizumab to delay or prevent type 1. Teplizumab is already being tested as a prevention method and is back in front of the FDA. NexImmune says it's wider plan is to use the body's own T-cells to generate a specific immune response to prevent not just diabetes but other auto immune conditions and even cancer. https://www.jdrf.org/press-releases/neximmune-yale-and-jdrf-enter-into-600k-research-partnership-for-type-1-diabetes/ XX Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the world's first Phase 3 study of oral insulin This is being looked at just for type 2 right now. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control, with a secondary endpoint of assessing the change from baseline in fasting plasma glucose at 26 weeks. They hope to announce results in January of 2023. https://www.biopharma-reporter.com/Article/2022/05/05/Oramed-hits-oral-insulin-clinical-trial-milestone XX New partnership between two diabetes heavy weights. The Diabetes Research Institute, DRI Foundation Canada (DRIFCAN) and Alberta Diabetes Institute (ADI) have announced a research partnership The CEO of DRI says "Type 1 diabetes knows no borders or boundaries; nor should the research to find a cure. There's a lot of research funded by these groups, included islet and stem cell transplantation. https://finance.yahoo.com/news/diabetes-research-institute-foundation-joins-193300513.html XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time,

Dexcom's G7 is in front of the FDA right now. There are some significant changes to the system, including what's basically a snooze for essential alarms, including the urgent low. Dexcom's Chief Technology Officer Jake Leach answers your questions about adhesive, direct to watch, accuracy, and even mentions the G8. Here's more information about the European approval (includes a video of the system) This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News..." Got a few minutes? Get caught up! Top stories this week: An FDA hiccup for Vertex, Omnipod 5 starts wider rollout, New peek at Dexcom G7 features, Beta Bionic study info, "Hey Alexa, predict my blood sugar" and Healthline shuts down their main source of diabetes news and information. -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story – bit of a surprise for Vertex – the FDA puts a clinical hold on their newest trial. This is the company that made big headlines last fall – that New York Times article likely sent to you by everyone you know about a stem cell cure for type 1. That's when Vertex reported data on the cell therapy from a single patient who achieved a "robust" restoration of islet cell function after receiving a drug called VX-880. That response is going strong they say at day 270. This week, Vertex showcased results from another patient and said a third patient has received the full dose. A company spokesman says they're surprised by the clinical hold given the evidence so far and there have been no serious adverse events. They say they'll work with the FDA to get the trial moving again as soon as possible. https://www.fiercebiotech.com/biotech/unwelcome-surprise-vertex-fda-slaps-hold-phase-12-diabetes-cell-therapy-study XX Insulet announces that Omnipod 5 has completed the Limited Market Release and will be rolling out to a wider audience soon. Those who signed up for what they call the interest list will be notified first – we're told watch for that email this week. If you haven't signed up, sit tight. Omnipod 5 still isn't yet available through all insurers and at every pharmacy, but the roll out will continue slowly through the year. https://www.omnipod.com/current-podders/resources/omnipod-5/faqs?fbclid=IwAR1fghbXl4uP4H3z8DGovriAocpZyDyPzLdPzME_taonv3_ZfPC3XqukHJY XX We're learning more about Dexcom's G7 – approved in Europe and in front of the US FDA right now. Sensors will have a bit of a grace period – they'll keep working 12 hours after the 10 days are up. You'll also be able to silence the urgent low and sensor fail alarms for six hours – that's new. I'm talking to CTO Jake Leach for next week's long-format show and he's got a lot of info to share. I asked as many of your questions as I could, so please come back for that one. XX New study results about the iLet, the insulin only bionic pancreas from Beta Bionics. This is one of the many studies presented at A-T-T-D.. People in the study saw about half a point come off their A1Cs after 13 weeks and there was no increase in hypoglycemia. They also saw more than 2 and a half hours more time in range. The iLet is unique in that you only enter your weight and tell the pump system when you're eating – there are no basal rates or a need to enter carbs. No timeline for release but the company says its regulatory submission is currently under FDA review. https://www.globenewswire.com/news-release/2022/04/30/2433019/0/en/The-iLet-Bionic-Pancreas-Significantly-Reduced-HbA1c-and-Improved-Time-in-Range-vs-Standard-of-Care-for-a-Diverse-Range-of-People-with-Type-1-Diabetes.html XX Amazon.com's online pharmacy PillPack has agreed to pay almost 6-million dollars to resolve claims that it overcharged government health insurance programs by dispensing more insulin injector pens than patients needed. That's the headline, but -editorial here – this story just shows a lot about what's wrong with our system. Many of us have had this happen – used to be if you had a prescription for insulin pens, they'd just give you the box of 5 – even if the prescription was written for 3 or 4. Now, they have to break open the box and count out the exact amount. It's not as though a patient was over-charged.. and that's not the focus of this lawsuit. This was about government health insurance programs. I get it, we're all paying for that in our taxes, but there's got to be a better way. Maybe pass that co-pay cap, or let Medicare negotiate prices or just cap the price overall. Then this issu

This week, we're having a conversation about diabetes beyond numbers. Yes, there are a lot of those and they are very important. But have you ever stopped to think about the mental energy and emotional effort behind those numbers? Even if your A1C and Time in Range are what your doctor wants to see. Our guests, Allison Nimlos and Sara Adams are therapists who both live with diabetes. They've come together to host a conference all about mental health and diabetes. Stacey asks them about a lot of very common issues and about how to start those conversations. The conference takes place May 20-21. It's virtual - click here for more info. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include headlines from the ATTD Conference - that's the Advanced Technologies and Treatments for Diabetes Conference. There's a bit of new information about the Dexcom G7, Beta Bionics announces it will release pivotal trial results, and news of the first AID system using the Libre 3 is announced. Along with ATTD there's news about type 2 diabetes and grocery stores, all types of diabetes and nursing homes and a person with T1D is on the cover of British Vogue. Learn more about T1D Exchange here Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX This week ATTD begins – that's the Advanced Technologies and Treatments for Diabetes Conference, so you can expect to hear a lot of news. I'll include some here, some next week and we've got future interviews lined up with a lot of the companies making headlines.. XX First up, a peek at more features in Dexcom's G7 system. It's approved in Europe but not the US and features what they're calling more meaningful alarms. You can silence more alarms, including urgent low & sensor fail for up to six hours, there's also a new 12 hour grace period at the end of the 10-day sensor life. It's already been announced the G7 has a much shorter warm up period, only half an hour, and is much smaller. -- Also at ATTD, Beta Bionics will be releasing Pivotal Trial Results of the iLet Bionic Pancreas. The iLet is a pump – connected to a CGM that is designed to autonomously determine and deliver insulin doses to control blood glucose levels. You'll recall this pump was originally designed to deliver both insulin and glucagon.. but the current iteration is insulin only. They says this pivotal trial population was more diverse and representative of the United States type 1 diabetes community than any previous pivotal trial of an automated insulin delivery system. We'll have more info on what these trials actually said next week. https://www.globenewswire.com/news-release/2022/04/25/2427846/0/en/Pivotal-Trial-Results-of-the-iLet-Bionic-Pancreas-To-Be-Presented-at-ATTD.html XX The first automated insulin delivery system using the FreeStyle Libre has been announced. This is in Europe and it's the Libre 3, Ypsomed pump and CamDiab software system. Expected by the end of the year, this is described as a self-learning app, a hybrid, closed-loop system that runs on an Android smartphone and can be tuned to users as young as one year old https://www.fiercebiotech.com/medtech/abbott-launches-diabetes-team-ypsomed-camdiab-bring-artificial-pancreas-system-europe XX And a new consensus meeting on Time in Range. In 2019, diaTribe formed the Time in Range Coalition, whose goal was to ensure that Time in Range (TIR) becomes the primary glucose metric for daily management, complemented by A1C, in diabetes care globally. But there isn't an internationally consensus on the use of CGMs in clinical trials. This meeting will help standardize those methods. XX Other highly anticipated – or at least well-publicized- studies coming to ATTD include those from Tandem and Omnipod and almost every big diabetes tech company. Lots more to come next week and we already have interviews set with Dexcom and Beta Bionics to we'll talk about all this in the long format episodes in weeks to come. XX Overtreating type 2 diabetes is apparently very common in nursing homes.. which can be a big problem as people get older and may require changes. New study in the Journal of the American Geriatric Society show about 40% of nursing home residents with type 2 diabetes may be overtreated. These researchers say one big issue is that at admission, residents are given a very big medical work up, but that isn't followed up on year to year. Often as people age, its recommended their A1C is maintained a bit higher, for safety reasons, so a target A1C could easily change years or even months after someone moves into assisted care or a nursing home. https://www.healio.com/news/endocrinology/20220422/diabetes-overtreat

Could this finally be a big shake up in the price of insulin? Civica Rx plans to sell the most popular types of fast and long acting insulin for a flat price of 30-dollars a vial. This week you'll hear from Ned McCoy, Civica's Chief Operating Officer. He explains why they're confident this will work, who will be able to buy the finished product, when it will be available and what Civica RX is all about. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include a new company called Luna Diabetes founded by some heavy-hitters in our community, a new #T1D telehealth study for underserved kids, improved life expectancy for people with type 2 and a look at 420 with diabetes. Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story is a very interesting LinkedIn post about a new company and product.. Luna Diabetes aims to fill in a big gap – overnight automated control for people who use smart insulin pens. They're calling it A-I – automated injections, a way to combine the convenience of insulin pens with the clinical outcomes of automated insulin delivery – like Control IQ or Looping. Some heavy hitters here – the founders are John Show-lund Sjolund – founder of Timesulin, John Brilliant a co-founder of BigFoot biomedical and Sean Saint, founder of Companion Medical who made the InPen automated pen system. The release shows a little device but no real information yet. Is it an automated basal delivery system for overnights only? pivotal trial to start by the end of this year We'll keep you posted.. https://www.lunadiabetes.com/ XX A look at pediatrics in under-served communities shows most children are not meeting A1C goals. A new grant from the Helmsley Charitiable Trust will focus on expanding access through remote care. Many providers lack the money to set remote care up and use it effectively – telehealth systems and things like that. A large pediatric endo group in Buffalo, NY will work with Cecelia Health, a virtual first health care provider. They'll work with about a thousand patients to explore how improving access to remote support and the internet to better manage chronic conditions will improve outcomes. This is along with existing diabetes technology like pumps and CGMs. https://www.benzinga.com/pressreleases/22/04/n26682238/improving-outcomes-for-children-and-adolescents-living-with-type-1-diabetes-is-the-goal-of-a-colla XX Big news for people with diabetes in Australia. The government has committed to subsidized access to continuous glucose monitoring and flash glucose monitoring technology for all people living with type 1 diabetes. Right now, people under 21 are already eligible as as women who are actively planning a pregnancy or are pregnancy. This agreement will make everyone eligible for just over 30-dollars a month. Right now it costs over 300-dollars a month. I'm going to link up info from the incredible Diabetes Australia advocate Renza Scibilia who's been on the show before and who's been working on this for more than ten years. Congrats Renza and all who will benefit. https://www.diabetesaustralia.com.au/mediarelease/diabetes-australia-welcomes-bipartisan-commitment-to-cgmforall/ https://diabetogenic.blog/2022/04/17/oh-happy-day/ XX Not a big surprise but important information about improving life expectancy in people with type 2. New study shows reducing A1C, blood pressure, cholesterol and BMI makes a big difference. This was a University of Florida Gainesville study.. biggest improvement in all of these was reducing A1C from the highest in the study – about 9.9 - to the lowest about - 7.7 - added almost 4 years of life expectancy. These researchers say it's very motivating to patients and clinicians to see these gains and it may help them choose treatment goals. https://medicalxpress.com/news/2022-04-treatment-goals-diabetes-life.html XX We've talked about One Drop before.. more than a meter, they now call themselves a digital coaching company. And a new evaluation from an independent, third-party found that One Drop's support program effectively improves the health of people living with prediabetes, diabetes, and high blood pressure. The program could also cut down on annual healthcare costs. This is from the independent Validation Institute, dedicated to providing unbiased, data-driven insights on hea

We don't need to tell you that the mental burden of diabetes is a heavy one. And most of us – caregivers and people with diabetes alike - are never given any resources to help. My guest this week is trying to help. Dr. Mark Heyman is a diabetes psychologist and lives with type 1 himself. His new book is called "Diabetes Sucks, and You Can Handle It." We talk about why he wanted to write the book, who it's for and what we can learn from his experiences. talk about some of the common fears and worries he hears and what he advises his patients. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about AFREZZA* *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

Sage Donnelly started kayaking with her father at age two, when he'd sit her in the boat next to him. She was diagnosed with type 1 diabetes at age 3 and got right back in the water. After watching competitions for several more years, at age seven she told her parents she wanted to compete. She wasn't kiddng! Donnelly was the Jr. Women's Freestyle World Championship and earned a spot in the Olympics. More recently, she's decided to go in another direction and shares what prompted the change. We talk about how she keeps her diabetes gear protected in the water, treating lows during 3-day remote adventures and more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. ----music----- Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include testing a new treatment for leukemia to see if it might help with type 1, Black patients with type 1 are at higher risk of DKA, transitioning from teen care to adult care, updates on Eversense in the US and Dexcom One in the UK and front office changes at Beyond Type 1 and Vertex. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Interesting look at whether a treatment for leukemia might work against type 1. Very early on here.. but AVM Biotechnology has received a grant to find out. The drug doesn't have a name yet.. it's referred to as AVM-0703 and has been shown to delay T1D in the lab. A preclinical dose-finding and mechanism of action (MOA) study in three scenarios including pre-diabetic, new-onset, and established diabetes is the first aim of the program. Those results will be used to determine the targeted dose to be used in a pivotal efficacy study for reversal of new-onset and established diabetes. It is anticipated that for patients not showing remission, AVM0703 may reinforce other immunotherapies allowing a wider range of patients to achieve insulin independence. https://www.businesswire.com/news/home/20220405005529/en/AVM-Biotechnology-Awarded-1.6-Million-Phase-II-SBIR-Grant-to-Study-AVM0703%E2%80%99s-Potential-to-Reverse-Type-1-Diabetes XX Black patients with type 1 faced a significantly higher frequency of diabetic ketoacidosis during the pandemic, and particularly during surges, researchers reported. This was a big study at several different health centers and hospitals. Researchers found there was not significant difference in the number of patients in DKA from 2019 versus 2020.. but there was a higher proportion of Black patients. The trend continued through the pandemic and again, it was significant, 48-percent versus 18 percent. Pandemic surges emphasized the disparity even more. These researchers say their work shows racial inequities in diabetes care were present before the pandemic, starkly visible during the pandemic, and will continue to persist after the pandemic -- unless we systemically root out and target racial inequities in diabetes care," https://www.medpagetoday.com/endocrinology/type1diabetes/98044 XX A new look the transition from pediatric to adult care for people with type 1 shows.. it needs improvement. This research – based on interviews with older adolescents showed many felt unprepared and dissatisfied with the transition process. Three big takeaways – the teens are aware of the changing relationship with their parents and health care teams and often want more independence than the parents are willing to give… the teens want acknowledgement that being diagnosed at different ages means they may be more or less comfortable with self-management and the third is that they think their pediatric team isn't preparing them to work with adult providers. Personally, this means a lot to me – as my son is 17 – and I'll be asking his peds endo to work with him more on this stuff in the next couple of years. https://www.healio.com/news/endocrinology/20220401/novel-programs-needed-to-improve-transition-from-pediatric-to-adult-diabetes-care XX DiabetesWise announces the launch of it's new Pro website. It's an unbranded non-biased resource created at Stanford University to help make providers more informed about diabetes devices and streamline the prescription process. We've talked about Diabetes Wise before and I'll link it up here. It's easy to feel overwhelmed by the evolving choices and providers are in the same situation. The DiabetesWise Pro website has an extensive Device Library where providers can learn about all of the FDA-approved diabetes devices on the market based on the patient's considerations. The user can compare the devices from the different manufacturers using the Compare Device tool, which displays a side-by-side analysis of the components and details of each technology, including the steps for ordering and prescri

It's always a privilege to talk to one of the Joslin Medalists. This week you'll hear from Laurie Harper. She was diagnosed as a toddler in 1955 and will mark 67 years with type 1 later this year. She shares what she remembers about her early years with diabetes, how her family adjusted, the technology she started with and what she uses now. The Joslin Medalist program recognizes and studies people who've lived with type 1 for at least 50 years. Laurie tells us more about the medalist program, about aging with diabetes and she takes a look back at how different the management was almost 70 years ago. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about the Joslin Medalist Program Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Our top stories this week include new information about the temperature at which insulin can be safely stored, a warning about men taking Metformin, news about sexual health and women with diabetes, and a heads up about a virtual mental health conference coming up for people with diabetes. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story.. a look at how insulin holds up under real-world and often hotter conditions than is recommended. Doctors without Borders found that a range of insulins can be stored at warmer temperatures than previously recommended. They showed it's okay above 77-degrees all the way up to 99 degrees for four weeks. This is really important not just for emergency settings like refugee camps but for people who live in areas without refrigeration. They often have to travel to health clinics which may be far away and which can't send them home with the insulin. The group now says pharmaceutical corporations should urgently submit to regulatory authorities for use of insulin under expanded temperature ranges. This came out a few weeks back, but I haven't seen it anywhere. https://www.doctorswithoutborders.org/latest/msf-study-shows-some-insulin-can-be-stored-warmer-temperatures XX Big headlines this week about Metformin and the risk of of birth defects in the babies of men who take it. Metformin is a very common diabetes drug, taken by tens of millions of people around the world. Sons born to men taking it were more than three times as likely to have a genital birth defect as unexposed babies. These problems were relatively rare, occurring in fewer than 1-percent of all babies with dads who took Metformin but it's significant because tens of millions of people worldwide take metformin. These researchers say the paper's findings are preliminary and observational only.. and that men with diabetes should NOT abruptly stop metformin before trying to conceive. Reassuringly, the researches saw no effect for men who took the drug earlier in life or even a year before. Expect a lot more research to come on this one. https://www.science.org/content/article/rare-genital-defects-seen-sons-men-taking-major-diabetes-drug XX Grain of salt needed here, but new research may show that people with type 1 are more likely to manage better if they have high levels of psychological resilience. This was a British study that followed 18-hundred people with type 1 or type 2 diabetes. They used a questionnaire to determine how they adapted to change and focused under pressure. The researchers found that people with type 1 diabetes who had low psychological resilience also had poorer blood sugar control after two years. The idea is that something like this would offer the opportunity to identify those who might benefit most from additional support when they are first diagnosed. https://medicalxpress.com/news/2022-03-psychological-resilience-future-high-blood.html XX Among patients with diabetes, women are just as likely as men to suffer from sexual dysfunction, but their issues are overlooked. Big session on this at the Diabetes UK Professional Conference this week. Reserachers say women with diabetes can experience reduced sexual desire, painful sex, and other issues which can increase the risk of depression. But these issues are usually untreated despite help being available. They talked about the embarrassment factor and the idea that many women with sexual dysfunction don't realize diabetes could be a factor. They encourage health care professionals to go beyond conversations about contraception, pregnancy and menstruation. A recent study led by Belgian researchers found that among more than 750 adults with diabetes 36% of men and 33% of women reported sexual dysfunction. https://www.medscape.com/viewarticle/971208 XX Concerning new trend about pre-diabetes.. it's doubled among children over the last 20 years. The increase was seen over almost all subpopulations of young Americans, reg

There's a new plan to manufacture and sell insulin at a much lower list price. The company behind it is non-profit Civica RX, which has support from JDRF. Stacey talks to JDRF CEO Aaron Kowalski about what their role is here, how realistic this plan is, who it may help and a lot more. They also spend some time talking about the reorganization of JDRF and what the future after COVID 19 looks like for them. More about Civica's Plan (we'll talk to them in a future episode) Here's the episode Stacey references with Thom Scher and Aaron Kowalski This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News..." Got a few minutes? Get caught up! Our top stories this week include increased risk of type 2 after having COVID-19, CGM gets high marks as a telehealth device, Ypsomed pump picks a new partner, more study on the TB vaccine for type 1 and T1D: The Movie update! -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX People who recover from a mild case of COVID-19 appear to have an increased risk for subsequent new-onset type 2 diabetes… but not other types of diabetes. This is from a big new study in Germany. It lines up with previous studies of more seriously ill patients with COVID 19 who had increased rates of type 2 in the months following. This was more than 35-thousand patients – no prior history of diabetes. The risk of developing type 2 increased by 28-percent if the person had COVID, again even a mild case. The researchers say anyone who tested positive for COVID should be aware and get screened for diabetes in the months and years following. https://www.medscape.com/viewarticle/970600 XX Big new study that – interestingly – talks about the CGM as a telehealth device. It looked at how doctors continued to care for children with type 1 before and after the first year of the COVID pandemic. The use of CGMs increased significantly among those with non-commercial insurance… from 24 percent in 2019 to 35 percent by the end of 2020. Another finding in this same study.. those with higher A1Cs, racial minorities, and those with non-commercial insurance were more likely to have high rates of DKA. But the implementation of telehealth and CGMs increased parental oversight which resulted in better care at home and lower than expected hospitalization rates. I want to dig a little deeper here because a lower hospitalization rate during the first year of the COVID pandemic overall.. was found to be tied to a lot of fear about going to a hospital during that time. https://mhealthintelligence.com/news/telehealth-helped-maintain-type-1-diabetes-care-among-kids-during-pandemic XX Swiss pump maker Ypsomed announces the software they'll use for their automated insulin delivery. Ypsomed will partner with CamDiab's CamAPS app. The launch will start in select major countries in Europe, with other territories to follow over the course of 2022. This includes a hybrid closed loop – like Omnipod 5 and Control IQ - as well as smartphone control.. it's compatible with Dexcom's G6. It'll start on Android then roll out on iOS.. Ypsomed is partnering with Lilly to come to the US – we've had them on the show before talking about this. They hope to submit to the FDA this year. https://www.drugdeliverybusiness.com/ypsomed-partners-with-camdiab-on-smartphone-based-automated-insulin-delivery/ XX The FDA is due to make a decision on Teplizumab by August 17th. This is a drug that has been shown to delay type 1 diabetes. Last year the FDA turned down Provention Bio, asking for a resubmission with more information. The company is also running the phase 3 PROTECT trial of teplizumab. That's in newly-diagnosed type 1 diabetes patients. They hope to expanding the indications for the drug. https://pharmaphorum.com/news/fda-sets-august-decision-date-for-proventions-type-1-diabetes-drug/ XX More study underway into the tuberculosis vaccine as a treatment for type 1. This is Dr. Denise Faustman's lab – they're recruiting 150 teen with type 1 for pediatric clinical trials of the shots. Faustman's work is controversial because her studies have been very small and many experts say they don't show significant improvement. But Faustman says the vaccine appears to help patients with Type 1 diabetes by altering their immune system and that even though no one in her trials is off of insulin, there is improvement. https://www.bostonglobe.com/2022/03/21/metro/could-100-year-old-vaccine-treat-type-1-diabetes-mgh-researchers-are-working-find-out/ XX If you're watching live, today is the last day to back the Kickstarter for Type 1 The Movi

There's been a lot of excitement recently about stem cell transplants and progress toward using this as a functional cure for type 1. There are a few separate groups working on this, this week we're talking to ViaCyte to get past the hype and look at the real progress here. You'll hear from ViaCyte's Head of Clinical Development Dr. Manasi Jaiman. ViaCyte has been studying stem cell transplants for several years – and recently started working with the gene editing technology CRISPR. We're going to talk about what this is all about, how close they really are, and who would even be in line to benefit. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM*

It's "In the News…" Got a few minutes? Get caught up! Top stories this week: Dexcom G7 approved in Europe, JDRF speaks out on non-profit insulin plan, Ukraine diabetes aid progress, texting for T2D, Reaction to Pixar's Turning Red -- Join us LIVE every Wednesday at 4:30pm ET Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Our top story this week.. Dexcom gets the CE Mark for it's new G7 system, which means it's approved in Europe. The approval is for people ages 2 and up, including pregnant women. I'm putting the full screen photo up here and I'll post this on the website and in the FB group for those listening.. interesting to finally get a good look at the much smaller applicator – as expected looks a lot like the Libre. Also interesting, all the PR for this has said, developed in partnership with Verily.. remember them? That was part of google, probably best known for saying they were going to develop a contact lens that would monitor glucose. I've reached out to Verily, love to know more about this partnership. Anyway, we've done a ton on G7, I'll link up some of our recent conversations with the folks at Dexcom. They submitted to the US FDA at the end of 2021, no firm timeline on US approval. https://www.medicaldevice-network.com/news/dexcom-ce-mark-g7-cgm-system/ XX Some good news about living longer with chronic conditions, including diabetes. This was a 20-year British study that ended in 2011, so one caveat here, it doesn't include COVID. Men gained 4-point-6 years of life expectancy; women gained 2-point-1. When it comes to disability-free life expectancy, men gained about a year less and women stayed the same. This included people with chronic conditions including those with diabetes. These researchers do point out that while they'd expect to see the same increase in the US – the lack of health and social safety net programs could make a negative difference here. But they point to CGM technology and better medication as making a big difference for those with diabetes. https://www.healthline.com/health-news/why-people-with-chronic-conditions-such-as-diabetes-are-living-longer-without-disability#Cognitive-impairment-is-the-exception XX Children who develop type 1 diabetes show epi-genetic changes in the cells of their immune system long before the antibodies of the disease are detected in their blood. An epigenetic change affects how our genes work. Outside factors such as environmental, viral infections, are usually the cause. These researchers say these are previously unknown changes that signal the increased risk of developing type 1 and could give an even earlier indication than the anti-body marker tests available now. https://www.news-medical.net/news/20220316/Epigenetic-changes-could-be-a-biomarker-for-early-detection-of-type-1-diabetes.aspx XX Could text-messaging with their doctors help people with type 2? A new team in Chicago is looking at text-based intervention in underserved communities. The intervention will deliver personalized information directly to patients through text messages, including reminders about self-monitoring and prescription refills, interactive office hours and general information about diabetes, motivational support and answers to frequently asked questions. These doctors say the idea is to create more opportunities for patients to meaningfully engage and reduce barriers by employing technology already in people's hands. https://today.uic.edu/an-sms-solution-for-type-2-diabetes XX Last week we told you about the effort by Civica RX to make affordable insulin. Civica, is a nonprofit generic pharmaceutical company. JDRF directed funds to this effort and CEO Aaron Kowalski wrote an op ed that I'll link up. In it, he talks about the success Civica has had lowering the costs of other medications. We'll have Kowalski on the show soon and I've reached out to Civica as well. This would lower the price to $35 a vial no matter your insurance. Congress still hung on a $35 co-pay cap for those with insurance. http

What happens when the diabetes community and the Star Trek fandom collide? The actor who brought these groups together spent time as a blue-skinned alien on Star Trek Discovery. Now Noah Averbach-Katz wants to make a movie where T1D is front and center. He shares more about the Kickstarter campaign to fund it, and about his time in the Star Trek world This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Stacey Simms 0:00 Diabetes Connections is brought to you by Omnipod take Omnipod dash out for a spin with a no commitment free 30 Day Trial, by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by club 1921, where Diabetes Connections are made. This is Diabetes Connections with Stacey Simms. This week when the diabetes community and the Star Trek fandom collide! The actor who brought these groups together spent time as a blue skinned alien with a lot of prosthetics on Star Trek Discovery, but he had to find a way to reach his fingers for blood sugar checks. Noah Averbach-Katz 0:45 I sort of explained that to him. And they said, Well, it's fine. We'll just put you in gloves the whole time. So the entire time of my sort of run of the show, I am wearing like black leather gloves. Regardless of what I'm doing. I'm eating breakfast, I'm wearing black leather gloves, I'm flying a spaceship, I'm I'm wearing black leather gloves. And that was just so I can have easy access to my fingers. So I could test. Stacey Simms 1:10 That's Noah Averbach-Katz . And while we talk a lot about Star Trek, he's really here to share the news about a movie he's making called type one. We've got all the info about the Kickstarter campaign to fund it, and other ways you can help. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Always so glad to have you along. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. I didn't plan it this way. But it's interesting. This is the second week in a row that we're doing more of a pop culture or media type episode about diabetes. Right? We talked about turning red last week, if you missed that episode, that is the new Pixar movie on Disney plus, that features two characters with diabetes in the background. And I talked to Susan Fogg from Pixar, who made that happen with her whole team, of course, and one of the things that Susan talked about was why it was just fine to have diabetes in the background, right? That's about what isn't her life. That's how it is for many people with diabetes. It's not always front and center. It's not always what you want to talk about. But this week's guest looked at things a little differently. And she'll hear Noah Averbach-Katz wanted to put diabetes front and center and make a movie that didn't feature it in the background. So while I didn't plan, as I said, you know, back to back here, I think it's an interesting contrast. Of course, the other big contrast is that Noah's movie is self-funded, it is on Kickstarter, I am going to link that up right here in the show notes. It'll be at diabetes connections.com. Very easy to get to, as we are taping the Kickstarter is still going on. But if you're listening to this after it is ending, the deadline is March 24 2022. And as you'll hear, he's already exceeded his goal. And we'll talk about how that happened. But it doesn't mean that he still doesn't need the money. This movie is expensive, all movies are expensive, and he shares about where the money will go, even as he has exceeded the goal. So if you are so inclined, I will link that up. You can head over there. There's a preview of the movie and more information. Noah was diagnosed with type one as a teenager, he will share that story. He's an actor, he has been featured in Star Trek Discovery. That's just one of the parts that he has had. And as he mentioned, he is married to Mary Wiseman, who has a starring role in Star Trek Discovery. When they got married in 2019. The New York Times did a write up and I will include that because it's a beautiful story. It's really well written. It's a lot of fun, but I will just share the headline here a life frequently apart, but an enterprise they'll boldly take on. There's a lot of Star Trek in this family. I do need to warn you know what is pretty blunt about diabetes. We all talk about this in different ways. Bu